HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $470

Benzinga Newsdesk www.benzinga.com Negative 48.0%

Neg 48% Neu 0% Pos 0%

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $510 to $470.